TWI645854B - 胚芽乳酸桿菌tci378及其於減脂及改善腸胃功能之應用 - Google Patents
胚芽乳酸桿菌tci378及其於減脂及改善腸胃功能之應用 Download PDFInfo
- Publication number
- TWI645854B TWI645854B TW107107478A TW107107478A TWI645854B TW I645854 B TWI645854 B TW I645854B TW 107107478 A TW107107478 A TW 107107478A TW 107107478 A TW107107478 A TW 107107478A TW I645854 B TWI645854 B TW I645854B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- tci378
- lactobacillus
- food
- fat
- Prior art date
Links
- 230000007661 gastrointestinal function Effects 0.000 title claims abstract description 18
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 9
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 230000004060 metabolic process Effects 0.000 claims abstract description 19
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 13
- 241000186660 Lactobacillus Species 0.000 claims description 54
- 229940039696 lactobacillus Drugs 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 38
- 239000002207 metabolite Substances 0.000 claims description 28
- 210000000577 adipose tissue Anatomy 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 235000013402 health food Nutrition 0.000 claims description 14
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 238000011160 research Methods 0.000 abstract description 3
- 239000003925 fat Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 22
- 210000001789 adipocyte Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000002775 capsule Substances 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091006300 SLC2A4 Proteins 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 235000021109 kimchi Nutrition 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 101100244177 Caenorhabditis elegans plin-1 gene Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 101150047829 plin-1 gene Proteins 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 235000019625 fat content Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000001406 Perilipin Human genes 0.000 description 2
- 108060006002 Perilipin Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 235000021102 Greek yogurt Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000017795 Perilipin-1 Human genes 0.000 description 1
- 108010067162 Perilipin-1 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000053 special nutrition Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- -1 tackifiers Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
一種胚芽乳酸桿菌(Lactobacillus plantarum
)TCI378,其係寄存於財團法人食品工業研究所(寄存編號為BCRC910760)、及德國國家菌種保藏中心(寄存編號為DSM32451),其可減少脂肪形成、增加脂肪代謝、及改善胃腸功能。
Description
本發明係關於一種新穎之胚芽乳酸桿菌(Lactobacillus plantarum
)TCI378。本發明亦關於胚芽乳酸桿菌TCI378及/或其代謝產物之應用,尤其是關於減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及/或改善胃腸功能之應用。
現代人因作息不正常、長期外食、生活壓力、缺乏運動等因素,代謝症候群、三高(高血糖、高血壓、高血脂)等疾病發生率不斷升高。從一開始的胃腸功能變差、新陳代謝變慢,使得每日攝取的熱量累積未被消耗、形成脂肪,乃致於後來的便秘、肥胖、慢性病等病症一一浮現,對人們的健康造成明顯的威脅。
雖然保持規律運動及多攝取蔬果可達到改善胃腸功能、促進脂肪代謝的效果,但對於忙碌且經常外食的現代人而言,仍需要其他更便利的方案。近年來,與改善胃腸功能、促進脂肪代謝相關的產品(如蔬果酵素)不斷推陳出新,益生菌(probiotics)亦成為熱門之研究方向。
嗜脂益生菌的出現曾為益生菌於減脂的應用帶來極大的希望,然專家後來指出,在目前的研究當中,尚未發現依賴消化脂肪以維生的益生菌。存在於人體腸道菌叢中的格蘭氏陰性病菌是依賴消化脂肪維生的細菌,當人體攝取過多脂質,格蘭氏陰性病菌會大量繁殖,其表面的脂多醣(lipopolysaccharide,LPS)會導致人體產生發炎反應,反而會引起肥胖、糖尿病、心血管疾病,甚至癌症。
乳酸桿菌(Lactobacillus)係存在於人體中的益生菌之一,可用於多種發酵食品的製備,且目前已有許多乳酸桿菌屬的菌株已被美國食品藥物管理局(Food and Drug Administration,FDA)分類屬於「公認安全(generally recognized as safe,GRAS)」的食品添加物。
本案發明人自韓國泡菜中篩選出一種新穎胚芽乳酸桿菌TCI378菌株,且經由實驗發現,該菌株及其代謝物具有減少脂肪形成、增加脂肪代謝、及改善胃腸功能之功效。
本發明之一目的,在於提供一種胚芽乳酸桿菌TCI378,其係寄存於財團法人食品工業發展研究所(寄存編號為BCRC 910760)、及德國國家菌種保藏中心(DSMZ)(寄存編號為DSM32451)。
本發明之另一目的,在於提供一種組合物,其係包含胚芽乳酸桿菌TCI378及其代謝產物。
本發明之又一目的,在於提供一種使用胚芽乳酸桿菌TCI378及其代謝產物於製備一組合物之用途。
上述根據本發明所提供之組合物係用於以下之至少一者:減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及改善胃腸功能。上述根據本發明所提供之組合物係一醫藥組合物、食品組合物、或飼料組合物。較佳地,該醫藥組合物係呈口服劑型。該食品組合物係一健康食品、保健食品、機能性食品、營養補充品或特殊營養食品。
本發明之詳細技術內容及部分具體實施態樣,將描述於以下內容中,以供本發明所屬領域具通常知識者據以明瞭本發明之特徵。
以下將描述根據本發明之部分具體實施態樣;惟,在不背離本發明精神下,本發明尚可以多種不同形式之態樣來實踐,不應將本發明保護範圍解釋為限於說明書所陳述者。此外,除非文中有另外說明,於本說明書中(尤其是在後述專利申請範圍中)所使用之「一」、「該」及類似用語應理解為包含單數及複數形式;所謂「個體」係指動物,該動物可以為哺乳動物(例如:人類)或非哺乳動物(例如:禽、鳥)。
韓國泡菜係被美國健康專業月刊《健康(Health)》評選為世界五大健康食品之一,雜誌中描述韓國泡菜不僅含有維生素A、B、及C,更含有乳酸桿菌,故與日本大豆、西班牙橄欖油、希臘優酪乳、以及印度扁豆一同被評選為世界五大健康食品。
本案發明人自韓國泡菜中篩選出一新穎菌株,經16S核糖體核糖核酸(16S rRNA)序列分析,依親緣關係鑑定為Lactobacillus plantarum
(中文名稱為胚芽乳酸桿菌株或植物乳酸桿菌),且經命名為Lactobacillus plantarum
TCI378(以下稱為胚芽乳酸桿菌TCI378),其係寄存於財團法人食品工業發展研究所(寄存編號為BCRC910760)、及德國國家菌種保藏中心(DSMZ)(寄存編號為DSM32451)。該胚芽乳酸桿菌TCI378係具有如SEQ ID NO: 1所示之16S核糖體核糖核酸(16S rRNA)片段。
本案發明人研究發現,胚芽乳酸桿菌TCI378及/或其代謝產物係具有減少脂肪形成、增加脂肪代謝、以及改善胃腸功能之功效。因此,本發明係提供一種胚芽乳酸桿菌TCI378、一種包含胚芽乳酸桿菌TCI378及/或其代謝產物之組合物、以及一種使用胚芽乳酸桿菌TCI378及/或其代謝產物於製備一組合物之用途,其中,該組合物係可用於以下之至少一者:減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及改善胃腸功能。
根據本發明,所採用之胚芽乳酸桿菌TCI378之代謝產物可以是透過在適於胚芽乳酸桿菌TCI378生長的環境下進行培養所產生者。例如:先以適當之培養液對胚芽乳酸桿菌TCI378進行培養,其後,視需要地去除前述培養液中之菌體等固體物,以獲得含有代謝產物之液體。
可選用任意合宜之培養液以進行胚芽乳酸桿菌TCI378之培養,以提供所欲之代謝產物,只要該培養液可提供胚芽乳酸桿菌TCI378生長、代謝所需養分(如酵母菌萃取物、蛋白質及葡萄糖)與條件(如酸鹼值)即可。此外,胚芽乳酸桿菌TCI378之培養時間亦無特殊限制,只要足以使胚芽乳酸桿菌TCI378完成至少一次代謝循環即可。舉例言之,於本發明一具體實施態樣中,係以MRS培養液對胚芽乳酸桿菌TCI378進行培養,歷時18小時,使菌株進行代謝作用並產生代謝產物。
於本發明中,係可直接使用經歷胚芽乳酸桿菌TCI378之代謝循環的含胚芽乳酸桿菌TCI378與代謝產物的培養液,或使用經移除胚芽乳酸桿菌TCI378等固體物之含代謝產物的液體。可採用任何合宜之操作以移除固體物,只要對培養後所產生的代謝產物之所欲效益沒有不利的影響即可。一般而言,係採用物理手段以移除固體物,該物理手段包括,例如:離心分離、濾膜過濾、沉澱傾析等操作。視需要地,可重複或合併進行前述物理操作,以盡可能去除培養液中的菌體等固體物。
根據本發明之應用所提供之醫藥組合物係可呈任何合宜的形式,並無特殊限制,端視所欲之用途而呈對應之合宜劑型。舉例言之,但不以此為限,該醫藥組合物可以口服之投藥方式施用至有需要的個體上。其中,視用途而定,可選用合宜之載劑以提供該醫藥組合物,其中,該載劑包括賦形劑、稀釋劑、輔助劑、安定劑、吸收延遲劑、崩散劑、增溶劑、乳化劑、抗氧化劑、黏合劑、結合劑、增黏劑、分散劑、懸浮化劑、潤滑劑、吸濕劑等。
於根據本發明所提供之醫藥組合物中係可含有任何不會不利影響活性成分(即,胚芽乳酸桿菌TCI378及其代謝產物)之所欲效益的醫藥上可接受之載劑,例如:水、食鹽水、葡萄糖(dextrose)、甘油、乙醇或其類似物、纖維素、澱粉、糖膨潤土(sugar bentonite)、及前述之組合。可利用任何合宜之方法,將該醫藥組合物以適於口服投藥的劑型提供,例如:錠劑(例如糖衣錠)、丸劑、膠囊劑、顆粒劑、散劑、流浸膏劑、溶液劑、糖漿劑、懸液劑、酊劑等。
根據本發明所提供之醫藥組合物係可以一日一次、一日多次、或數日一次等不同投藥頻率施用,端視投予個體之需求、年齡、體重、及健康狀況而異。於根據本發明所提供之醫藥組合物中,可視實際應用需求,調整胚芽乳酸桿菌TCI378及/或其代謝產物於組合物中的含量比例。此外,該醫藥組合物可視需要另含一或多種其他活性成分,或者與含該一或多種其他活性成分之藥物併用,以進一步加強該醫藥組合物之功效或增加製劑配方的運用靈活性與調配度,只要該其他活性成分對本發明活性成分(即,胚芽乳酸桿菌TCI378及/或其代謝產物)之效益沒有不利的影響即可。
根據本發明所提供之食品組合物係可以為健康食品、保健食品、機能性食品、營養補充品、或特殊營養食品,且可製成例如乳製品、肉類加工品、麵包類、麵食類、餅乾、***錠、膠囊、果汁類、茶類、運動飲料、營養飲料等產品,但不以此為限。
根據本發明所提供之健康食品、保健食品、機能性食品、營養補充品、及特殊營養食品係可以一日一次、一日多次、或數日一次等不同頻率食用,端視投予個體之年齡、體重、及健康狀況而異。亦可針對特定族群之需要,調整據本發明所提供之健康食品、保健食品、機能性食品、營養補充品、及特殊營養食品中的胚芽乳酸桿菌TCI378及/或其代謝產物的含量,例如,調整至每日應服用的量。
針對根據本發明所提供之健康食品、保健食品、機能性食品、營養補充品及/或特殊營養食品,可於其外包裝上標示建議使用量、特定族群(例如高血脂患者、孕婦等)的使用標準及條件、或與其他食品或醫藥共同服用的建議事項等,以利使用者在無醫師、藥師或相關執事人員的指導下自行服用而無安全虞慮。於根據本發明所提供之食品組合物中,有關該胚芽乳酸桿菌TCI378及/或其代謝產物之態樣,係如上述之說明。
視需要地,可於根據本發明所提供之醫藥組合物、食品組合物、或飼料組合物中另外含有合宜用量之添加劑,例如可提高該醫藥組合物、食品組合物、或飼料組合物於服用時的口適感及視覺感受之調味劑、調色劑、著色劑等,以及可改善該醫藥組合物、食品組合物、或飼料組合物的穩定性及儲存性之緩衝劑、保存劑、防腐劑、抗菌劑、抗真菌劑等。
本發明亦提供一種減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及/或改善胃腸功能的方法,其係包含對一有需要之個體投予一組合物,其中該組合物係含有有效量之胚芽乳酸桿菌TCI378及/或其代謝產物。,有關該胚芽乳酸桿菌TCI378及/或其代謝產物之態樣,亦如上述之說明。
茲以下列實施例進一步例示說明本發明。其中該等實施例僅提供作為說明,而非用以限制本發明之保護範圍。本發明保護範圍係如後附申請專利範圍所示。
實施例
[
製備實施例
]
A.
胚芽乳酸桿菌
TCI378
之篩選與鑑定
(A-1
)篩選
將韓國泡菜之均質物(包含泡菜及醬汁)與MRS培養液(MRS broth)以體積比1:100的比例混合,並置於37℃下進行厭氧培養(氧氣濃度低於5%),歷時18小時。其後,將前述培養液塗佈於MRS固態培養基(MRS agar)上,並置於37℃下進行厭氧培養,以生成不同的菌落。接著,為確保菌株的單一性,使用無菌接種環挑選一菌落,於固態培養基上進行分區劃線,再置於37°C之厭氧培養箱中培養直到單一菌落(single colony)出現。
(A-2
)鑑定
取(A-1)所分離出之單一菌落的菌株,進行基因族譜分析(phylogenetic analysis),確認該菌株具有如SEQ ID NO:1所示之16S核糖體核糖核酸(16S rRNA)片段。使用NCBI(National Center for Biotechnology Information)線上資料庫進行比對,確認該SEQ ID NO:1係與胚芽乳酸桿菌(Lactobacillus plantarum)菌株之16S核糖體核糖核酸(16S rRNA)片段係具有約99%之相似度,故依親緣關係鑑定該標的菌株係為胚芽乳酸桿菌,且命名為胚芽乳酸桿菌TCI378。
(A-3
)保存
使用液態培養的方式將(A-1)所獲得之具單一性之菌株培養於MRS培養液中,以提供菌液,接著於菌液中添加25%之甘油,將所得混合液移至冷凍保存管中後,置於-80℃保存。
B.
胚芽乳酸桿菌
TCI378
之活化與樣品製備
(B-1
)活化
將存有胚芽乳酸桿菌TCI378菌株之冷凍保存管解凍,以1%之植菌量(約1x104
CFU/mL)將TCI378菌株接種於MRS培養液中,並置於37℃下進行厭氧培養,歷時18小時,以提供胚芽乳酸桿菌TCI378菌液,供後續實驗使用。
(B-2
)樣品製備
取(B-1)提供胚芽乳酸桿菌TCI378菌液,以1%之植菌量(約1x104
CFU/mL)接種於MRS培養液之中,並置於37℃下進行厭氧培養,歷時18小時。其後,以5000rpm轉速對培養後之菌液進行離心,歷時5分鐘,再使用0.2μm的濾膜對所獲得之上清液進行過濾,所得濾液即為TCI378樣品(含有胚芽乳酸桿菌TCI378之代謝產物)。
C.
脂肪細胞培養
(C-1
)細胞培養液
(1) 前脂肪細胞增殖培養液(pre-adipocyte expansion medium): -90% 杜氏改良依格爾培養液(Dulbecco's Modified Eagle's Medium;購自Gibco); -10% 牛血清(Bovine Serum;購自Gibco);以及 -1% 盤尼西林-鏈黴素溶液(Penicillin-streptomycin;購自Gibco)。 (2) 分化培養液(differentiation medium): -90% 杜氏改良依格爾培養液(購自Gibco); -10% 胎牛血清(Fetal Bovine Serum;購自Gibco); -1% 盤尼西林-鏈黴素溶液(購自Gibco); -1.0 微莫耳/毫升 迪皮質醇(Dexamethasone;購自Sigma); -0.5 毫莫耳/毫升甲基異丁基黃嘌呤(Methylisobutylxanthine;購自Sigma);以及 -1.0 微克/毫升 胰島素(購自Sigma)。 (3) 脂肪細胞維持培養液(adipocyte maintenance medium) -90% 杜氏改良依格爾培養液(購自Gibco); -10% 胎牛血清(Fetal Bovine Serum;購自Gibco); -1% 盤尼西林-鏈黴素溶液(購自Gibco);以及 -1.0 微克/毫升 胰島素(購自Sigma)。
(C-2
)脂肪細胞分化
以每孔8x104
顆細胞的細胞數,將老鼠纖維母細胞株3T3-L1細胞(購自財團法人食品工業發展研究所,BCRC 60071)種植於24孔盤中,並以(C-1)之前脂肪細胞增殖培養液於37℃培養48小時,其後將細胞培養液替換成(C-1)之分化培養液,再於37℃下培養4天,接下來再將細胞培養液置換成(C-1)之脂肪細胞維持培養液,繼續於37℃培養8天,以獲得一脂肪細胞,供後續實驗使用。
實施例
1
:胚芽乳酸桿菌
TCI378
及其代謝產物於減脂之功效
(
1-1
)細胞處理
取[製備實施例C-2]提供之脂肪細胞,分成三組,並分別以如下表之條件,置於37℃下培養48小時:
(
1-2
)油紅
O
脂肪染色
以磷酸鹽緩衝液(PBS)潤洗(1-1)提供之各組細胞二次,接著於各組加入1.0毫升之10%甲醛並靜置於室溫下30分鐘,以固定細胞。其後,將甲醛移除並以PBS潤洗各組細胞二次,再於各組加入1.0毫升之50%之異丙醇,靜置1分鐘後將異丙醇移除。最後,於各組加入1.0毫升之油紅O溶液,並於室溫靜置一小時以將油滴染色。移除油紅O溶液後,以PBS潤洗各組細胞二次,並以顯微鏡觀察脂肪細胞之油滴狀況並拍照記錄,結果示於圖1(箭頭所指之深色對比部分即為脂肪油滴)。
待完成上述脂肪細胞油滴之觀察與記錄後,以100%之異丙醇處理各組細胞10分鐘,將堆積的油滴溶出,然後偵測波長於510nm下的吸光值,以檢測各組之脂肪含量。最後,以控制組的結果為基準(即,將控制組的脂肪含量設定為1倍),計算其他二組的相對脂肪含量,結果示於圖2。
由圖1可知,相較於控制組,TCI378組的細胞其油滴明顯縮小,空白組細胞之油滴則沒有顯著變化。由圖2可知,無論是相較於控制組或是空白組,TCI378組細胞的脂質含量皆下降約15%。前述結果顯示,胚芽乳酸桿菌TCI378及/或其代謝產物可有效降低脂肪細胞中的脂質含量。
(
1-3
)基因表現分析
已知蛋白質Perilipin可保護脂肪細胞油滴不被破壞,若可減少Perilipin的表現量,即可使脂肪細胞之油滴容易被分解,進而增加脂肪代謝。此外,已知GLUT4
基因表現增加會影響脂肪細胞對於葡萄糖的吸收,進而產生脂肪酸而導致肥胖,若能減少GLUT4
基因表現量,即可減少脂肪形成。為確認胚芽乳酸桿菌TCI378及/或其代謝產物是否具有促進脂肪代謝及/或減少脂肪形成的效果,本實施例係進行以下分析,以檢測胚芽乳酸桿菌TCI378對PLIN1
基因(即,表現Perilipin蛋白的基因)及GLUT4
基因表現的影響。
收集(1-1)提供之各組細胞,以核糖核酸純化套組(RNA purification kit;購自GeneMark)進行RNA萃取,並以反轉錄酶套組(SuperScript™ Reverse Transcriptase kit;購自Invitrogen)將該RNA反轉錄為cDNA。接著,以SYBR Green Master Mix(購自KAPA)及ABI StepOne Plus™ System對前述之cDNA進行qPCR(quantitative polymerase chain reaction),以檢測PLIN1
基因及GLUT4
基因的表現量。以控制組的結果為基準(即,將控制組的基因表現量設定為1倍),計算萃取物組的基因相對表現量。結果示於圖3及圖4。
由圖3及圖4可知,無論是相較於控制組或空白組,TCI378組之PLIN1
基因及GLUT4
基因之表現量皆有明顯較低。
(1-2)及(1-3)的結果顯示,本發明之胚芽乳酸桿菌TCI378及/或其代謝產物確實具有減少脂肪形成及增加脂肪代謝的效果,故可降低脂肪細胞中的脂質含量,使個體不易形成體脂肪。
實施例
2
:胚芽乳酸桿菌
TCI378
於減脂及改善腸胃功能之功效
招集10位受試者(體脂肪皆大於27、且未服用任何減肥食品或藥物者)。於實驗開始前(即,服用含有胚芽乳酸桿菌TCI378之膠囊以前),先請各受試者自我評估是否有排便不乾淨之情形(由「沒有」、「偶爾」、「有時候」、「總是」等選項中進行選擇),並測量體重、腰圍、BMI值、全身體脂率、軀幹體脂率。接著,請受試者於每日午餐過後服用一顆含有胚芽乳酸桿菌TCI378之膠囊(每顆膠囊含有5x109
CFU之胚芽乳酸桿菌TCI378),連續服用14天(即,各受試者係服用該膠囊14次)。其後,再次請各受試者評估是否有排便不乾淨之情形,並測量體重、腰圍、BMI值、全身體脂率、及軀幹體脂率。最後,將10位受試者之體重、腰圍、BMI值、全身體脂率、及軀幹體脂率取平均值,結果示於圖5至圖9。另一方面,係將受試者自我評估之「排便不乾淨」的結果進行統計,以受試者的總數為基準(即,設為1),計算「沒有」、「偶爾」、「有時候」、或「總是」有排便不乾淨情形之受試者的比例,結果示於圖10。
由圖5至圖9可知,相較於服用含有胚芽乳酸桿菌TCI378之膠囊以前(第0天),受試者於連續服用膠囊14天後(第14天),無論是全身體脂率或是軀幹體脂率,皆有顯著下降的趨勢。相較於第0天,受試者之體重、腰圍、及BMI值亦皆顯著降低。此外,由圖10可知,受試者於連續服用含有胚芽乳酸桿菌TCI378之膠囊14天後,排便不乾淨之情形亦有改善的趨勢。
上述結果表示,受試者於服用含有胚芽乳酸桿菌TCI378之膠囊後,其脂肪堆積的情形與胃腸功能皆得到改善,進而達到體重、BMI值、及腰圍皆下降的效果。因此,本發明所提供之胚芽乳酸桿菌TCI378及其代謝產物確實可用於以下之至少一者:減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及改善胃腸功能。
圖1至圖4分別顯示脂肪細胞經過不同培養液處理之後的結果,其中,圖1顯示細胞經處理後之染色照片圖且箭頭所指深色區域為油滴,圖2顯示以控制組為基準之各組細胞的脂質相對含量(**表示與控制組有顯著差異,p<0.01;##表示與空白組有顯著差異,p<0.01),圖3顯示以控制組為基準之各組細胞的PLIN1
基因表現量(*表示與控制組有顯著差異,p<0.05;**表示與控制組有顯著差異,p<0.01;#表示與空白組有顯著差異,p<0.05),圖4顯示以控制組為基準之各組細胞的GLUT4
基因表現量(**表示與控制組有顯著差異,p<0.01;#表示與空白組有顯著差異,p<0.05),且其中,控制組僅以脂肪細胞維持培養液進行培養,空白組係以含有1%MRS培養液之脂肪細胞維持培養液進行培養,TCI378組則使用含有1%TCI378樣品之脂肪細胞維持培養液進行培養;
圖5至圖9顯示胚芽乳酸桿菌TCI378之減脂效益,分別顯示受試者於第0天(即,服用含有胚芽乳酸桿菌TCI378之膠囊以前)及第14天(即,連續服用該膠囊14天後)之全身體脂率(圖5,*表示與第0天有顯著差異,p<0.05)、軀幹體脂率(圖6,*表示與第0天有顯著差異,p<0.05)、體重(圖7,**表示與第0天有顯著差異,p<0.01)、腰圍(圖8,*表示與第0天有顯著差異,p<0.05)、以及BMI值(圖9,**表示與第0天有顯著差異,p<0.01);以及
圖10胚芽乳酸桿菌TCI378之改善腸胃功能效益,顯示受試者於第0天及第14天時之排便情形。
TW中華民國 財團法人食品工業發展研究所 2016/12/27 BCRC910760
DE德國 德國國家菌種保藏中心DSMZ(Deutsche Sammlung von Mikroorganismen und Zellkulturen) 2017/3/13 DSM32451
<110> 大江生醫股份有限公司 <120> 益生菌Lactobacillus plantarum TCI 378及其於減脂及改善腸胃功能之應用 <130> <150> US 62/473,785 <151> 2017-03-20 <160> 1 <170> PatentIn version 3.5 <210> 1 <211> 1076 <212> DNA <213> Lactobacillus plantarum <220> <223> 16S rRNA片段 <220> <221> misc_feature <222> (118)..(118) <223> n 為 a、c、g、或 t <220> <221> misc_feature <222> (184)..(184) <223> n 為 a、c、g、或 t <400> 1 gctggcggcg tgctatacat gcagtcgaac gaactctggt attgattggt gcttgcatca 60 tgatttacat ttgagtgagt ggcgaactgg tgagtaacac gtgggaaacc tgcccagnag 120 cgggggataa cacctggaaa cagatgctaa taccgcataa caacttggac cgcatggtcc 180 gagnttgaaa gatggcttcg gctatcactt ttggatggtc ccgcggcgta ttagctagat 240 ggtggggtaa cggctcacca tggcaatgat acgtagccga cctgagaggg taatcggcca 300 cattgggact gagacacggc ccaaactcct acgggaggca gcagtaggga atcttccaca 360 atggacgaaa gtctgatgga gcaacgccgc gtgagtgaag aagggtttcg gctcgtaaaa 420 ctctgttgtt aaagaagaac atatctgaga gtaactgttc aggtattgac ggtatttaac 480 cagaaagcca cggctaacta cgtgccagca gccgcggtaa tacgtaggtg gcaagcgttg 540 tccggattta ttgggcgtaa agcgagcgca ggcggttttt taagtctgat gtgaaagcct 600 tcggctcaac cgaagaagtg catcggaaac tgggaaactt gagtgcagaa gaggacagtg 660 gaactccatg tgtagcggtg aaatgcgtag atatatggaa gaacaccagt ggcgaaggcg 720 gctgtctggt ctgtaactga cgctgaggct cgaaagtatg ggtagcaaac aggattagat 780 accctggtag tccataccgt aaacgatgaa tgctaagtgt tggagggttt ccgcccttca 840 gtgctgcagc taacgcatta agcattccgc ctggggagta cggccgcaag gctgaaactc 900 aaaggaattg acgggggccc gcacaagcgg tggagcatgt ggtttaattc gaagctacgc 960 gaagaacctt accaggtctt gacatactat gcaaatctaa gagattagac gttcccttcg 1020 ggacatggat acaggtggtg catggttgtc gtcagctcgt gtcgtgagat gttggg 1076
Claims (8)
- 一種胚芽乳酸桿菌(Lactobacillus plantarum)TCI378,其係寄存於財團法人食品工業發展研究所(寄存編號為BCRC910760)、及德國國家菌種保藏中心(DSMZ)(寄存編號為DSM32451)。
- 一種組合物,其包含如請求項1之胚芽乳酸桿菌TCI378及/或其代謝產物。
- 如請求項2之組合物,其係用於以下之至少一者:減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及改善胃腸功能。
- 如請求項3之組合物,其係一醫藥組合物、食品組合物、或飼料組合物。
- 一種使用如請求項1之胚芽乳酸桿菌TCI378及/或其代謝產物於製備一組合物之用途,其中該組合物係用於以下之至少一者:減少脂肪形成、增加脂肪代謝、使個體不易形成體脂肪、及改善胃腸功能。
- 如請求項5之用途,其中該組合物係一醫藥組合物、食品組合物、或飼料組合物。
- 如請求項6之用途,其中該組合物係醫藥組合物且呈口服劑型。
- 如請求項6之用途,其中該組合物係食品組合物,且該食品組合物係一健康食品、保健食品、機能性食品、營養補充品、特殊營養食品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762473785P | 2017-03-20 | 2017-03-20 | |
US62/473,785 | 2017-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201834675A TW201834675A (zh) | 2018-10-01 |
TWI645854B true TWI645854B (zh) | 2019-01-01 |
Family
ID=63521394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107107478A TWI645854B (zh) | 2017-03-20 | 2018-03-06 | 胚芽乳酸桿菌tci378及其於減脂及改善腸胃功能之應用 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20180264054A1 (zh) |
JP (1) | JP6630388B2 (zh) |
KR (1) | KR102033031B1 (zh) |
CN (1) | CN108624523B (zh) |
TW (1) | TWI645854B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI725464B (zh) * | 2018-07-03 | 2021-04-21 | 大江生醫股份有限公司 | 減脂之益生菌株及其組合物與用途 |
JP7130287B2 (ja) * | 2018-12-12 | 2022-09-05 | 生合生物科技股▲ふん▼有限公司 | プロバイオティクス組成物の製造方法 |
CN111297912A (zh) * | 2018-12-12 | 2020-06-19 | 生合生物科技股份有限公司 | 胚芽乳酸杆菌twk10制备抗运动后发炎或降体脂组合物的用途 |
KR102177552B1 (ko) * | 2018-12-28 | 2020-11-11 | 건국대학교 산학협력단 | 락토바실러스 프란타룸 g72 균주를 포함하는 위장관 질환 예방 또는 치료용 조성물 |
TWI747280B (zh) * | 2019-05-17 | 2021-11-21 | 大江生醫股份有限公司 | 余甘子萃取發酵物及其製備與應用 |
TWI757911B (zh) * | 2019-10-07 | 2022-03-11 | 大江生醫股份有限公司 | 奇異果發酵汁液用於改善肌膚狀況的用途 |
CN110684701B (zh) * | 2019-11-19 | 2021-02-12 | 西南大学 | 植物乳杆菌s58及其在制备用于缓解肥胖的产品中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100422309C (zh) * | 2004-09-29 | 2008-10-01 | 光明乳业股份有限公司 | 植物乳杆菌st-iii的减肥用途 |
CN101864375A (zh) * | 2010-01-15 | 2010-10-20 | 吉林省农业科学院 | 一株具有降胆固醇功能的植物乳杆菌及其应用 |
CN103598594A (zh) * | 2013-10-28 | 2014-02-26 | 天津科技大学 | 植物乳杆菌在降血脂和辅助减肥方面的应用 |
CN104928208A (zh) * | 2015-04-30 | 2015-09-23 | 江苏紫石微康生物科技有限公司 | 一种植物乳杆菌Lp90及其筛选方法和应用 |
CN105105145A (zh) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5053667B2 (ja) * | 2006-12-28 | 2012-10-17 | 日清ファルマ株式会社 | 新規乳酸菌および脂肪細胞分化促進用乳酸菌発酵産物 |
JP2008214253A (ja) | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | 内臓脂肪減少剤 |
US20140328814A1 (en) * | 2008-05-13 | 2014-11-06 | Oü Tervisliku Piima Biotehnoloogiate Arenduskeskus (Bio-Competence Centre of | Antimicrobial and antihypertensive probiotic composition, food product and dietary supplement comprising microorganism strain lactobacillus plantarum tensia dsm 21380 and method for suppressing contaminating microbes in a food product |
NZ712603A (en) * | 2013-04-17 | 2020-02-28 | Suntory Holdings Ltd | Composition containing bacterium belonging to genus lactobacillus |
JP2015008672A (ja) * | 2013-06-28 | 2015-01-19 | 東海漬物株式会社 | 発酵食品とその製造方法、および新規乳酸菌 |
JP2015096476A (ja) * | 2013-11-15 | 2015-05-21 | 株式会社東洋新薬 | コラーゲン産生促進用組成物、コラーゲン吸収促進用組成物、抗肥満用組成物 |
US9399048B2 (en) * | 2014-03-05 | 2016-07-26 | Asian Probiotics And Prebiotics Ltd | Lactic acid bacteria and its applications in immunomodulation and anti-inflammation |
CN106103696B (zh) | 2014-03-24 | 2020-01-17 | 大塚制药株式会社 | 新颖的拟干酪乳杆菌菌株 |
CN104073455B (zh) * | 2014-06-18 | 2016-06-01 | 兰州大学 | 一株具有降低胆固醇能力的植物乳杆菌 |
KR102125548B1 (ko) * | 2015-02-10 | 2020-06-24 | 주식회사 지니스 | 비만 억제능을 갖는 균주 및 이를 함유하는 약학 조성물 |
KR101611834B1 (ko) * | 2015-06-08 | 2016-04-14 | 주식회사 쎌바이오텍 | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 락토바실루스 플란타룸 cbt lp3 균주 및 이를 포함하는 조성물 |
KR101670048B1 (ko) * | 2016-07-26 | 2016-10-27 | (주)메디톡스 | 개체의 지방 함량을 감소시키는 미생물 및 그의 용도 |
-
2018
- 2018-03-06 TW TW107107478A patent/TWI645854B/zh active
- 2018-03-14 CN CN201810210650.7A patent/CN108624523B/zh active Active
- 2018-03-19 KR KR1020180031585A patent/KR102033031B1/ko active IP Right Grant
- 2018-03-19 JP JP2018051654A patent/JP6630388B2/ja active Active
- 2018-03-20 US US15/926,413 patent/US20180264054A1/en not_active Abandoned
-
2020
- 2020-04-21 US US16/854,676 patent/US11273189B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100422309C (zh) * | 2004-09-29 | 2008-10-01 | 光明乳业股份有限公司 | 植物乳杆菌st-iii的减肥用途 |
CN101864375A (zh) * | 2010-01-15 | 2010-10-20 | 吉林省农业科学院 | 一株具有降胆固醇功能的植物乳杆菌及其应用 |
CN103598594A (zh) * | 2013-10-28 | 2014-02-26 | 天津科技大学 | 植物乳杆菌在降血脂和辅助减肥方面的应用 |
CN104928208A (zh) * | 2015-04-30 | 2015-09-23 | 江苏紫石微康生物科技有限公司 | 一种植物乳杆菌Lp90及其筛选方法和应用 |
CN105105145A (zh) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108624523A (zh) | 2018-10-09 |
TW201834675A (zh) | 2018-10-01 |
KR20180106987A (ko) | 2018-10-01 |
JP2018153182A (ja) | 2018-10-04 |
US11273189B2 (en) | 2022-03-15 |
CN108624523B (zh) | 2020-10-02 |
US20180264054A1 (en) | 2018-09-20 |
KR102033031B1 (ko) | 2019-10-17 |
JP6630388B2 (ja) | 2020-01-15 |
US20200254034A1 (en) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI645854B (zh) | 胚芽乳酸桿菌tci378及其於減脂及改善腸胃功能之應用 | |
KR101825836B1 (ko) | 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 당뇨 또는 인슐린 저항성 증후군의 예방 및 치료용 약학적 조성물 | |
TWI759126B (zh) | 使用乳酸菌菌株的液態培養物來抗發炎以及治療發炎性障礙 | |
EP2223697B1 (en) | Lactic acid bacterium-containing preparation | |
JP2016216408A (ja) | 筋肉の分解抑制剤 | |
CN114096657A (zh) | 新的普氏粪杆菌菌株eb-fpdk11及其用途 | |
TWI719549B (zh) | 促進嗜黏蛋白艾克曼菌生長之益生質組合物 | |
JP6458059B2 (ja) | 決明子乳酸菌発酵物を有効成分とする便秘改善、治療又は予防用組成物及びその製造方法 | |
JP6761268B2 (ja) | Mkp−1誘導剤 | |
CN109069521A (zh) | 粪杆菌属细菌增殖剂 | |
JP5612870B2 (ja) | 褥瘡改善作用を有する組成物 | |
TWI764295B (zh) | 加氏乳桿菌tci943或其代謝產物及其用於改善肌膚狀況的用途 | |
KR20180040894A (ko) | 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물 | |
JP7267536B2 (ja) | 乳酸醗酵ニンジンの製造方法 | |
CN112190644A (zh) | 植物发酵物及其制备方法与用于胃脏保健的用途 | |
CN110839693A (zh) | 吉氏副拟杆菌在预防或治疗肥胖或其相关疾病中的应用 | |
JP6836298B1 (ja) | 乳酸菌及び納豆菌を含む組成物 | |
TW201943852A (zh) | 可改善高血壓之羅伊氏乳桿菌菌株gmnl-263及其組合物 | |
TWI754302B (zh) | 乳雙歧桿菌tci604及其代謝產物的應用 | |
TWI817342B (zh) | 益生質組合物及其用途 | |
US20220387524A1 (en) | Novel kimchi-derived lactobacillus fermentum strain with excellent anti-inflammatory activity and composition including same for prevention and treatment of inflammatory diseases | |
CN109321484B (zh) | 具有治疗结肠直肠癌能力的戊糖乳杆菌05b0100分离株及其用途 | |
VICTOR-ADULOJU | EVALUATION OF WOUND-HEALING POTENTIALS OF PROBIOTICS ISOLATED FROM LABORATORY-PRODUCED „KUNUN-ZAKI‟ ON STREPTOZOTOCIN-INDUCED DIABETIC RATS. | |
CN114053342A (zh) | 促进排便的组合物及其应用 | |
CN116548609A (zh) | 益生质组合物及其用途 |